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Background: Lung cancer is the leading cause of cancer-related death worldwide, with 5-year overall 
survival less than 15%. Therefore, it is essential to find biomarkers for early detection and prognosis. 
Aberrant DNA methylation is a common feature of human cancers and its utility is already recognized 
in cancer management. The aim of this study was to explore the diagnostic and prognostic value of the 
promoter methylation status of the ASC/TMS1/PYCARD and MyD88 genes, key adaptor molecules in the 
activation of the innate immune response and apoptosis pathways. 
Methods: A total of 50 non-small cell lung cancer (NSCLC) patients were enrolled in the study. Meth-
ylation of bisulphite converted DNA was quantified by pyrosequencing in fresh frozen malignant tissues 
and adjacent non-malignant tissues. Associations between methylation and lung function, tumor grade and 
overall survival were evaluated using receiver-operating characteristics (ROC) analysis and statistical tests of 
hypothesis.
Results: Methylation level of tested genes is generally low but significantly decreased in tumor tissues (ASC/
TMS1/PYCARD, P<0.0001; MyD88, P<0.0002), which correlates with increased protein expression. Three 
CpG sites were identified as promising diagnostic marker candidates; CpG11 (-63 position) in ASC/TMS1/
PYCARD and CpG1 (-253 position) and 2 (-265 position) in MyD88. The association study showed that the 
methylation status of the ASC/TMS1 CpG4 site (-34 position) in malignant and non-malignant tissues is 
associated with the overall survival (P=0.019) and the methylation status of CpG8 site (-92 position) is associ-
ated with TNM-stage (P=0.011). 
Conclusions: The methylation status of the ASC/TMS1/PYCARD and MyD88 promoters are promising 
prognostic biomarker candidates. However, presented results should be considered as a preliminary and 
should be confirmed on the larger number of the samples.
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Introduction
Lung cancer is the leading cause of cancer-related death 
worldwide which makes it a serious health and economical 
problem. In addition, the 5-year survival rate is still less 
than 15%. Since lung cancer is mostly diagnosed at the 
advanced stage of disease and known therapeutic approaches 
are still not efficient enough, it is of particular importance 
to identify new biomarkers that could be used for early 
detection and prognosis assessment. Since epigenetic 
alterations are more frequent than genetic mutations in 
cancer genome, a promising approach for early cancer 
diagnosis emerged in form of epigenetic biomarkers (1). 
Epigenetic changes can be described as stable and heritable 
chromatin changes which could have an effect on gene 
expression, without changing the DNA sequence itself (2). 
Epigenetic alterations that include variability in DNA 
methylation contribute to the overall  phenotypic 
characteristics of an individual and can participate in the risk 
for malignancy development (3). If CpG islands of the gene 
promoter region are affected by aberrant methylation, this 
can significantly contribute to tumor promotion (3,4). Thus, 
tumor suppressor gene hypermethylation is recognized as 
a hallmark of lung cancer and tends to occur as an early 
event in the carcinogenic process (5,6). In contrast to 
hypermethylation, genomic hypomethylation is thought to 
occur late in carcinogenesis in NSCLC, and gene-specific 
hypomethylation is also recorded for several genes involved 
in the promotion of lung cancer (1,7). Additionally, it is well 
known that lung cancer development is strongly associated 
with chronic inflammation that could be influenced by DNA 
methylation (8). If acute inflammation is not regulated, 
it can lead to chronic inflammation and may contribute 
to cancer initiation, progression and dissemination (9). 
During the last decade multiple studies have shown that 
respiratory immune cells, epithelial and mesothelial cells, 
upon endogenous or exogenous injury, act together to 
trigger inflammation via activation of pattern recognition 
receptors (PRRs) (10-12). Toll-like receptors (TLRs), 
one of the best characterized PRRs receptors are known 
to be associated with immune and inflammatory diseases 
through dysregulated production and release of IFNs and 
proinflammatory cytokines (13,14). TLRs are activated 
either by pathogen-associated molecular patterns (PAMPs), 
or danger-associated molecular patterns (DAMPs), 
released at sites of infection or by tissue damage (15). 
Critical adaptor protein in TLR signaling is MyD88 
(Myeloid differentiation primary response protein 88). 
Initiation of the TLR signaling lead to a complex signaling 
cascade culminating in activation of different transcription 
factors, such as nuclear factor κB (NF-κB) and interferon 
regulatory factors (IRFs) (16,17). Besides TLRs other 
PPRs, NLRs (NOD-like receptors), can also be activated 
by specific ligands and form a multiprotein platform called 
inflammasome upon ligand binding (18). Inflammasome 
formation is required for activation of caspase-1 and 
subsequent secretion of proinflammatory cytokines, IL-18 
and IL-1β, a process that promote carcinogenesis (19) and 
support tumor survival by triggering secretion of several 
factors, such as VEGF, FGF2 or STAT3 (20). A critical 
adaptor molecule in inflammasome assembly and activation 
through homologous interactions is ASC (apoptosis-associated 
speck-like protein containing a caspase recruitment domain), 
a bipartite intracellular signalling molecule composed of 
both N-terminal pyrin domain (PYD) and the C-terminal 
caspase-recruitment domain (CARD) (21). A synonym for 
ASC used in the literature is TMS1 (Target of Methylation 
induced Silencing protein 1). The inflammasome complex can 
activate caspase-8 dependent apoptotic cell death, but also 
caspase-1 dependent pyroptotic cell death (22). Given the 
important role of ASC/TMS1/PYCARD gene in activation 
and subsequent regulation of inflammation in the tumor and 
non-tumor tissues, methylation of the CpG islands in the 
promoter region was the subject of many studies. Aberrant 
hypermethylation of the promoter region of ASC/TMS1/
PYCARD has been reported in many different human 
neoplasms such as renal carcinoma (23), breast cancer (24), 
colorectal cancer (25), glioblastoma (26), hepatocellular 
carcinoma (27), melanoma (28), neuroblastoma (29), non-
small cell lung and small cell lung cancer (30), ovarian 
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tumors (31), prostate cancer (32) and thyroid cancer (33). 
This could lead to the conclusion that ASC/TMS1/
PYCARD might be a tumor suppressor gene, and its 
silencing could promote carcinogenesis of some tumor 
types. Thereby, it is assumed that the ASC/TMS1/PYCARD 
tumor-associated methylation can serve as a potential target 
for the development of improved therapeutic treatments, 
or as a diagnostic and prognostic predictor. Since alteration 
of MyD88 expression is associated with the constitutive 
activation of NF-κB signaling, MyD88 is supposed to have 
a role in carcinogenesis as well. Several groups have shown 
that increased protein expression of MyD88 is associated 
with generally worse outcome in different tumor types. It 
has been shown that increased MyD88 expression is linked 
to poor prognosis of patients with colorectal cancer (34) 
and TLR4-mediated paclitaxel chemoresistance in ovarian 
cancer (35). In breast cancer there is an association with 
increased MyD88 protein expression and metastasis, TNM 
stage and poor overall survival (35), and similar findings 
were noticed in NSCLC (36). However, no published 
data could be found for the methylation status of MyD88 
promoter region. On the other hand, several studies 
have been published dealing with the evaluation of the 
methylation status of ASC/TMS1/PYCARD, measured by 
methyl-specific PCR approach (MSP), and relationship 
between methylation status and protein expression and 
different clinical outcomes in different tumor types, 
including lung cancer. Many of them, if not all of them, 
detected that aberrant hypermethylation of CpG islands, in 
the ASC/TMS1/PYCARD promoter region is linked with 
silencing of gene expression in various cancers including 
prostate cancer (32), breast cancer (24), gastric cancer (37) 
and NSCLC (38). For example, Virmani et al. (30) found 
that promoter hypermethylation (147 bp upstream of 
ATG site) is the cause of loss of gene expression in SCLC 
and breast cancer. They also reported that the ASC/
TMS1/PYCARD promoter was methylated in 41% of 
SCLC and in 32% of breast tumor tissues. Furthermore, 
Zhang et al. (38) reported hypermethylation of ASC/
TMS1/PYCARD gene in NSCLC and Machida et al. (39) 
found that hypermethylation of ASC/TMS1/PYCARD 
occurs at late stages of lung cancer, not present at earlier 
stages. The DNA methylation status of promoter sites of 
the specific genes may represent a promising biomarker 
for early detection, precise diagnosis and treatment of 
several human cancers. Using DNA methylation status as 
a biomarker would have potential advantages, comparing 
to other markers, since it can be detected with a broad 
spectrum of affordable techniques (1,7). It is worth to 
mention that widely used non-quantitative technology, 
such as MSP, usually failed to quantify methylation status 
correctly because significant proportion of lowly methylated 
samples are recognized as methylated indicating a very high 
sensitivity even for low levels of DNA methylation (40). 
This might lead to overestimation of DNA methylation. 
Therefore, in the current study, we aim to re-evaluate the 
methylation status of ASC/TMS1/PYCARD and MyD88 
genes in the NSCLC tumor samples and paired non-
tumor tissue using a pyrosequencing approach, highly 
sensitive quantitative method. The aim of the study was to 
evaluate if methylation status of tested genes possess the 
potential to serve as diagnostic or prognostic biomarkers. 
We investigated the correlation of methylation of the 
aforementioned gene promoters with overall survival and 
tumor grade (TNM stage). 
Methods 
Tissue samples
Resected, early-stage NSCLC tissues (adenocarcinoma 
and squamous cell carcinomas) with the adjacent non-
malignant lung parenchyma from treatment-naïve patients 
(N=50) were obtained during surgery at Clinical Hospital 
Center Zagreb, Department for Respiratory Diseases 
Jordanovac. Tissue samples were snap frozen in liquid 
nitrogen and kept stored at −80 ℃ for further analysis. The 
pathologic diagnosis of each case was confirmed by the 
review of hematoxylin and eosin stained slides, according 
to the WHO 2015 (REF). Only sections with a minimum 
of 70% tumor cells advanced to phase of DNA/RNA/
protein extraction. Tumors were staged according to the 
International Union Against Cancer (UICC) TNM staging 
system, 8th edition (41). Clinical and pathological features 
of the patients are shown in the Table 1. All patients signed 
informed consent and the study was approved by the local 
ethic committee (University Hospital Centre Zagreb, 
Department for Respiratory Diseases).
DNA isolation, bisulphite conversion, PCR and pyrosequencing
Genomic DNA was isolated from tumor and non-tumor 
tissues with the DNeasy blood and tissue kit (Qiagen) 
according to the manufacturer’s instructions and quantified 
using a NanoDrop 2000 spectrophotometer. Bisulphite 
conversion was performed on 450 ng DNA of each sample 
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using the Epitect 96 bisulphite kit (Qiagen) according to 
the manufacturer’s instructions. Pyrosequencing primers 
were designed using PyroMark Assay Design Software 2.0 
(Qiagen). The primers were designed to cover a total of 11 
CpG sites located in the 5'-flanking promoter region and 
the surrounding area of exon 1 of the ASC/TMS1/PYCARD 
gene and a total of 10 CpG sites in the 5' flanking promoter 
region of the MyD88 gene (Figure 1). A prediction analysis 
(AliBaba2.1) has shown that both analysed ASC/TMS1/
PYCARD and MYD88 regions contain a high density of CpG 
sites and transcription factors binding sites characteristic 
for regulatory domains. PCR primers for ASC/TMS1/
PYCARD: F_Bio-5'-GAGGTTTGGGTGGGAGG, R-5'-
AATCTCCAAATAAAAACTAACCAAC; SeqPrimer 
1_5'-GTTTTTTGTTGGAGGGTAA; SeqPrimer 
2_5'-CAACTTCAACTTAAACTTCTT. PCR primers 
for MyD88: F_5'-TATGTTGAGAGTAGTTAGGG; R_
Bio_5'-TATAAACCCCTCAAATTCCTC; SeqPrimer 
1 _ 5 ' - T G G T G AT G G T G T TA G TA ;  S e q P r i m e r 
2 _ 5 ' -  G A G AT T T G G A G A G G T T;  S e q P r i m e r 
3_5'-GGGGTGTTTATTTTTATT. PCR reactions 
were carried out in 25 µL final volume containing 2.5 µL 
of reaction buffer, 0.5 µL (10 mmol) dNTP mix, 0.2 µL 
FastStartTaq DNA polymerase (1U, Roche), 1 µL of 
forward and reverse primers (10 pmol final concentration), 
18.8 µL of UltraPure Nuclease-Free Water and 1 µL of 
bisulphite-treated DNA. Pyrosequencing was performed 
on a PyroMark Q96 ID platform (Qiagen) with PyroMark 
Gold Q96 reagent kit (Qiagen) according to manufacturer’s 
instructions. Data were analysed using the PyroMark CpG 
Software 1.0.11 (Qiagen). 
RNA extraction and RT-Qpcr
RNA was isolated from tumor and adjacent non-malignant 
tissues using a commercial RNeasy Mini Kit (Qiagen), 
according to the manufacturer’s protocol. Quality and 
integrity of the RNA was determined by RIN number using 
a 2100 Bioanalyzer and the RNA 6000 Nano Kit (Agilent 
Technologies). Samples with RIN numbers of 5 and higher 
were used for downstream analysis. In order to reduce the 
cost of the analysis, the same amount of the RNAs, with 
highest RIN scores, isolated from three tumor sample 
tissues were used for cDNA synthesis of the tumor mix 
(200 ng total RNA input; RT2 First Strand Kit) according 
to manufacturer’s instruction (Qiagen). cDNAs were tested 
by RT2PCR assay (PAHS-097ZA-2, Qiagen) according to 
manufacturer’s instructions. Adjacent non-malignant tissues 
were processed in the same way. CT values were exported 
and analysed by the data analysis web portal (http://www.
qiagen.com/geneglobe). 
Protein extraction and immunoblot analysis
Proteins were isolated from tissue slices (10 µm). Briefly, 
tissue slices were incubated for 30 minutes on ice in Passive 
Lysis buffer (Promega), followed by centrifugation on +4 ℃ 
at 21000 G for 30min (Eppendorf Centrifuge 5810R). After 
centrifugation, supernatant with proteins was carefully 
collected. Protein concentration was determined using BCA 
assay (PierceTM BCA Protein Assay Kit, Thermo scientific), 
according to manufacturer’s instructions. Proteins (100 µg) 
were denatured for 10 min at 95 ℃ in sample buffer (2ME, 
glycerol, bromophenol blue, Tris-HCl) and loaded on 10% 
SDS gels. SDS-PAGE electrophoresis was performed at 
180 V. Proteins were transferred to a 0.2 µm nitrocellulose 
Table 1 Clinicopathologic characteristics of lung cancer patients
Characteristic  N (%)
Age at diagnosis, years, median (range) 63 [38–79]
Histologic type
Adenocarcinoma 33 (66.0)
Squamous-cell carcinoma 17 (34.0)
T-stage
1 7 (14.0)
2 34 (68.0)
3 7 (14.0)
4 2 (4.0)
N-stage
0 31 (62.0)
1 14 (28.0)
2 5 (10.0)
TNM-stage
1 20 (40.8)
2 20 (40.8)
3 8 (16.3)
4 1 (2.0)
†FEV1, %, mean (SD) 81.21±19.84
Data are presented as number (%), unless otherwise indicated 
†FEV1, forced expiratory volume in one second.
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membrane in case of MyD88, or to a PVDF membrane 
in case of ASC/TMS1 (BIO-RAD), each using the Trans 
Blot TurboTM Transfer System (BIO-RAD). Membranes 
were incubated overnight at +4 ℃ with monoclonal 
mouse anti-MyD88 (NBP2-27369-Novus Biologicals, 
1:100) and polyclonal goat anti-ASC/TMS1 (AF3805- 
R&D Systems, 1:200) primary antibodies, respectively. 
Monoclonal mouse anti-Vinculin [(7F9): sc-73614, Santa 
Cruz-Biotechnology, 1:1,000] was used as housekeeping 
control. Secondary antibodies used were HRP-labelled anti-
mouse (170-6516-BIO-RAD, 1:10,000) or anti-goat (P0449, 
DAKO-Agilent Technologies, 1:5,000). Luminol based 
substrate was used for protein imaging (Clarity™ Western 
ECL, BIO-RAD) with Uvitec Imager (UVItec, Cambridge, 
UK). Intensity of the bands was quantified using the ImageJ 
program.
Statistical analysis
Differences in methylation status and protein expression 
between tumor and healthy tissue samples were tested 
using a paired t-test. Associations of methylation status and 
clinical variables were tested using an independent samples 
t-test and one-way analysis of variance (ANOVA) with 
Tukey-Kramer’s post-hoc test for pairwise comparison. Data 
are presented as mean ± standard error of the mean (SEM). 
To assess the diagnostic properties of indicated biomarker, 
receiver operating characteristic (ROC) curves were plotted 
and the areas under curves (AUC) together with 95% 
confidence intervals (95% CIs). Impact of clinical variables 
and methylation status on overall survival (OS) was assessed 
by the Kaplan-Meier method and survival curves were 
compared by the log-rank test. Median was used as a cut-off 
to dichotomize continuous variables. Association between 
methylation status and pulmonary function was assessed 
by calculating Spearman’s rank correlation coefficient (ρ). 
Only P values ≤0.05 were considered statistically significant. 
Statistical analyses were performed using GraphPad Prism 
version 5.0 for Windows (GraphPad Software, La Jolla, 
California, USA) and MedCalc for Windows, version 19.0.5 
(MedCalc Software, Ostend, Belgium). AliBaba2.1 (http://
gene-regulation.com/pub/programs/alibaba2/) program was 
used for predicting potential binding sites of transcription 
factor binding sites.
Figure 1 Sequence map of ASC/TMS1/PYCARD and MyD88 gene promoter. (A) The analysed CpG sites are located at 134–65 bp upstream 
or 33–52 bp downstream of ASC/TMS1/PYCARD transcription start site (ATG); (B) the analysed CpG sites are located between −278 
and −146 bp upstream of the MyD88 transcription start site. The vertical lines in the upper panels represent individual promotor CpG sites. 
Arrows indicate transcription start sites. Underlined CpG sites were analysed.
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Results 
Methylation status of the ASC/TMS1/PYCARD and 
MyD88 in the tumor and adjacent non-malignant tissues 
of NSCLC patients 
We quantified the overall promoter methylation status and 
the methylation status of individual CpG sites located in 
the ASC/TMS1 and MyD88 promoter regions. The aim 
of this analysis was to define the methylation levels of the 
NSCLC patient’s tumor and adjacent non-malignant tissue 
and to see if any of the tested sites could be considered as 
a potential tumor-tissue marker. The methylation status 
of all tested CpG sites in all tested samples is represented 
as an average value of the methylation (%) of at least three 
individual PCR/pyrosequencing reactions (Tables S1,S2). 
Pyrosequencing analysis showed an overall methylation 
of the ASC/TMS1/PYCARD gene promoter in tumor 
tissues is significantly decreased (average 6.58%; 4.43–
Figure 2 Methylation status of the ASC/TMS1/PYCARD and MyD88 in the tumor and adjacent non-malignant tissues. (A) Correlation anal-
ysis of overall promoter methylation in non-tumor vs. tumor tissue from NSCLC patients. Each data point represents the mean percentage 
methylation (%) across the tested region of 11 tested CpG sites in the ASC/TMS1/PYCARD gene promotor (left panel) and 10 CpG sites in the 
MyD88 promoter (right panel). (B) Methylation status of individual CpG sites in the ASC/TMS1/PYCARD and MyD88 gene promoters. Each 
bar represents mean percentage methylation (%) of individual CpG sites. A grey bar represents healthy tissues and dark bars tumor tissues. The 
left panel corresponds to ASC/TMS1/PYCARD and right panel to MyD88. For (A) and (B) data were analysed using the paired t-test; P≤0.05 is 
considered significant. Data are presented as mean ± SEM. **, P≤0.01; ***, P≤0.001. (C) ROC analysis. The panels show the ROC analysis for 
ASC/TMS1/PYCARD CpG11 (panel 1) and MyD88 CpG1, 2 and 4 (panels 2, 3 and 4) to differentiate tumor from non-tumor tissue.
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13.54%) compared to non-malignant tissues (average 
7.41%; 6.50–9.09%, P<0.0001) (Figure 2A, left panel). 
Overall methylation of the MyD88 promoter region was 
also significantly lower in tumor tissues (average 6.26%; 
0.71–9.20%) compared adjacent non-tumor tissues (average 
7.88%; 2.35–10.02%, P<0.0002 ) (Figure 2A, right panel). 
Aiming to define the diagnostic value of the tested CpG 
sites, we compared the methylation status (%) of individual 
CpG sites in tumor and adjacent non-malignant tissues. For 
ASC/TMS1/PYCARD we found that decreased methylation 
of CpG site 11, located at position -63, upstream of the 
transcription start site (TSS), is common trait of all tested 
NSCLC tumor samples (average 4.56%; 0–9.42%), 
compared to adjacent non-tumor tissue (average 7.65%; 
4.05–16.83%; P<0.001) (Figure 2B, left panel). For MyD88, 
we found that decreased methylation of CpG site 1 (located 
at position -253 upstream of the TSS; average 8.57%; 
2.75–24.24%), CpG site 2 (located −256 upstream of TSS; 
average 13.16%; 4.86–33.76%) and CpG site 4 (located 
at −278 upstream of TSS; average 12.26%; 0–28.45%) 
are common trait of all tested NSCLC tumor samples 
compared to non-tumor samples (average CpG1 12.61%, 
3.49–22.35%, P<0.001; average CpG2 18.83%, 11.91–
30.25%, P<0.001; average CpG4 15.50%; 8.81–45.77%, 
P<0.01) (Figure 2B, right panel).
In order to check if differentially methylated CpG sites 
could have some diagnostic applications, we performed 
ROC curve analysis. The ROC analysis indicated that 
CpG sites in ASC/TMS1 (CpG11) and MyD88 (CpG1 
and CpG2) are promising biomarker candidates for 
differentiation of NSCLC tissue vs surrounding non-
malignant tissue because corresponding areas under curve 
(AUC) were 80–90% (Figure 2C). Since an AUC ≥0.75 
generally indicates a marker that could potentially have 
clinical utility (42), we classified those CpG sites as a marker 
with good accuracy. This suggests that methylation status 
of specific CpG sites in the ASC/TMS1 and MyD88 genes 
are promising biomarker candidates for differentiation of 
NSCLC from surrounding non-malignant tissue.
RNA and protein expression of ASC/TMS1/PYCARD 
and MyD88 in tumor and non-tumor tissue samples from 
NSCLC patients 
In order to evaluate if the significantly decreased 
methylation of the ASC/TMS1/PYCARD and MYD88 
promoters in tumor tissues, detected in this study, could 
impact protein expression, we isolated whole proteins 
from tumor and adjacent non-malignant pairs of tissue 
lysates. Samples with low whole protein concentration 
were excluded. We quantified the protein expression level 
and found that ASC/TMS1/PYCARD and MyD88 are 
significantly higher expressed in NSCLC tumor tissues 
compared to non-tumor tissues (P=0.0011 for ASC and 
P=0.0207 for MyD88) (Figure 3A). These data indicate 
that the slightly decreased methylation of the ASC/TMS1/
PYCARD and MyD88 genes in tumor tissues, observed in 
this study, could be potentially associated with increased 
protein expression. 
Aiming to invest igate the impact  of  decreased 
methylation on mRNA expression level in tumor and 
adjacent non-tumor tissue pairs, we performed RT-qPCR, 
using a predesigned array comprising 84 inflammasome-
related genes, including ASC/TMS1and MyD88. Out of 84 
tested panel genes, 77 showed normal fluorescence curves 
in both runs. Out of these 77 successfully amplified genes, 
36 genes were up-regulated in tumor tissue while 9 were 
downregulated, in comparison to non-tumor tissue. All 
tested genes and the detailed report of gene expression 
are shown in Table S3. Tumor specific genes exhibited the 
highest expression level, with fold-change higher than 
5 were: CARD18 (Caspase Recruitment Domain family 
member 18), AIM2 (Absent In Melanoma 2), PANX1 
(Pannexin 1), FADD (Fas Associated via Death Domain), 
MOK (MOK protein kinase), IRAK1 (Interleukin 1 
Receptor Associated Kinase 1), TNFSF4 (Tumor Necrosis 
Factor SuperFamily member 4), NFKBIB (NFκB Inhibitor 
Beta), MAPK13 (Mitogen-Activated Protein Kinase 13) 
and NOD2 (Nucleotide Binding Oligomerization Domain 
Containing 2). ASC/TMS1/PYCARD was also up-regulated 
(Fold Up-regulation 2.27), while expression of MyD88 was 
not changed. Among the most significant tumor-specifically 
downregulated genes were IL33 (Interleukin 33), IL6 
(Interleukin 6) and NLRP9 (NLR Family Pyrin Domain 
Containing 9) (Figure 3B). 
Association of ASC/TMS1/PYCARD and MyD88 
promoter methylation with overall survival and tumor 
stage 
In order to evaluate if differentially methylated CpG sites 
could be associated with any prognostic or diagnostic 
characteristic, we performed an association study on overall 
survival (OS), TNM status and lung function. 
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Association of methylation levels and clinical variables
Association analysis of the methylation status of ASC/
TMS1/PYCARD promoter CpG sites pointed out that 
methylation level of certain sites is associated with TNM 
stage of the NSCLC patients. Post hoc analysis (Tukey-
Kramer) showed that CpG3 is significantly higher 
methylated in tumor samples with T-stage 1 when 
compared to T-stage 2 (P=0.023). CpG10 is significantly 
higher methylated in non-malignant samples with T-stage 
1 when compared to all other T-stage samples (T2, 3 and 
4) (P<0.001). CpG11 is significantly higher methylated in 
T-stage 1 non-malignant tissues when compared to T-stage 
2 and 3 (P=0.016). CpG6 is significantly higher methylated 
in adjacent non-malignant tissue samples with N-stage 1 
when compared to N-stage 2 (P=0.007). M-stage was not 
analyzed because only 2 patient samples were positive for 
metastasis. CpG8 is significantly higher methylated in 
malignant tissues with TNM-stage 2 when compared to 
TNM-stage 1 (P=0.011) (Figure 4A). Association analysis 
of the methylation status of MyD88 promoter CpG sites 
indicated that CpG6 is significantly higher methylated in 
T-stage 1 malignant samples when compared to T-stage 2 
(P<0.001). CpG8 in non-malignant tissues is significantly 
higher methylated in T-stage 1 samples when compared 
with T-stage 2 (P<0.016) (Figure 4B). To conclude, it seems 
that loss of methylation of the specific CpG sites in the 
ASC/TMS1/PYCARD and MyD88 genes might be indicator 
of the advanced tumor stage and the regional lymph node 
status of the NSCLC patients. All results of the association 
analyses of ASC/TMS1/PYCARD and MYD88 methylation 
status and investigated clinical variables are presented in 
Table 2. 
Association of overall survival with clinical variables 
and methylation levels
Follow-up data used for OS were obtained from medical 
records. Survival data was obtained for 49 patients, of whom 
12 (24.5%) died during the follow-up period. Two of them 
died immediately after diagnosis and were excluded from 
survival analyses. The median follow-up time was 48 months 
(range, 1–58 months). OS time was measured from the date 
of diagnosis to the time of death by any cause. Detailed 
results of survival analysis are presented in Tables 3,4. 
Among clinicopathological characteristics, both highest 
N-stage and TNM-stage were significantly associated with 
shorter OS of lung cancer patients (P=0.0007 and P=0.023, 
respectively) (Figure 5A,B). TNM-stage 3 patients have five 
times higher chances to die compared to stage 2 patients 
Figure 3 Protein expression and mRNA expression profile of ASC/TMS1/PYCARD in tumor and non-tumor tissues. (A) Protein expression 
levels in tumor tissue are significantly higher than in non-tumor tissue for both ASC/TMS1/PYCARD (P=0.0011) and MyD88 (P=0.0207). 
Tissue lysates were analysed by Western blot with anti-ASC/TMS1/PYCARD, anti-MyD88 and anti-Vinculin antibodies. Intensity of the 
bands was measured using ImageJ software. Graphs represent the intensity of the respective bands, expressed as relative intensity normalized 
to Vinculin. Data are presented as mean ± SEM. (B) Profiles of 84 inflammasome-related genes on mRNA level. Total RNA was extracted, 
transcribed to cDNA and analysed for the expression of 84 genes involved in inflammasome signaling pathway measured with the RT2 
Profiler PCR Array-PAHS-097ZA-2. Shown are the fold change values in arbitrary units. Data were normalized to B2M housekeeping gene.
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(HR 5.31, 95% CI 1.39–20.25) and twelve times higher 
chances compared to stage 1 patients (HR 12.39, 95% CI 
1.88–81.83). When we compared methylation level of the 
tested CpG sites with OS we found that lower methylation 
levels of ASC/TMS1/PYCARD CpG4 (below the median 
value), in both non-tumor and tumor tissue, are associated 
with shorter OS (P=0.019 for both) (Figure 5C,D). These 
patients have an eight times higher probability to die 
compared to patients with higher ASC/TMS1/PYCARD 
CpG4 methylation levels (HR 8.11, 95% CI 2.02–32.56). 
Similarly, lower methylation of ASC/TMS1/PYCARD 
CpG8 in tumor tissue is also associated with shorter 
overall survival (P=0.017, HR 8.38, 95% CI 2.08–33.70) 
(Figure 5E). In conclusion, it seems that decreased 
Figure 4 Statistically significant associations of ASC/TMS1/PYCARD and MYD88 methylation levels and clinical variables. (A) Methylation 
levels of specific ASC/TMS1/PYCARD CpG sites significantly associated with T-, N- and TNM-stage; (B) methylation levels of two MyD88 
CpG sites are significantly associated with T-stage. Black rectangle represents mean value and bars represent ± SEM. *, P≤0.05; **, P≤0.01; 
***, P≤0.001.
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methylation of the specific CpG sites in the ASC/TMS1/
PYCARD gene could be a predictor of poor OS in the 
NSCLC patients.
Correlation between pulmonary function and 
methylation levels
Correlation analysis between FEV1 (lung function measured 
in forced expiratory volume in 1 second) and ASC/TMS1/
PYCARD or MyD88 methylation levels have shown 
weak positive correlations with level of MyD88 CpG1 
site methylation in the tumor tissue (ρ=0.36, P=0.030), 
Table 2 Association of ASC/TMS1/PYCARD and MYD88 methylation levels and clinical variables
CpG site Tissue type
ASC/TMS1/PYCARD MYD88
T-stage N-stage TNM-stage Age T-stage N-stage TNM-stage Age
CpG1 H 0.101 0.195 0.763 0.531 0.198 0.409 0.737 0.968
T 0.275 0.665 0.596 0.175 0.202 0.257 0.625 0.557
CpG2 H 0.735 0.874 0.781 0.482 0.281 0.535 0.694 0.588
T 0.381 0.771 0.702 0.095 0.458 0.369 0.404 0.672
CpG3 H 0.642 0.455 0.436 0.091 0.387 0.864 0.909 0.795
T 0.023 0.682 0.810 0.457 0.193 0.070 0.232 0.414
CpG4 H 0.768 0.168 0.162 0.495 0.483 0.805 0.763 0.264
T 0.865 0.511 0.590 0.062 0.094 0.147 0.153 0.357
CpG5 H 0.688 0.411 0.474 0.703 0.067 0.963 0.502 0.472
T 0.173 0.469 0.630 0.025 0.339 0.620 0.662 0.796
CpG6 H 0.322 0.007 0.170 0.913 <0.001 0.345 0.810 0.824
T 0.146 0.612 0.703 0.116 0.366 0.332 0.509 0.816
CpG7 H 0.828 0.481 0.943 0.048 0.183 0.935 0.799 0.718
T 0.531 0.479 0.100 0.064 0.065 0.581 0.999 0.641
CpG8 H 0.994 0.739 1.000 0.784 0.016 0.964 0.894 0.306
T 0.764 0.132 0.011 0.474 0.309 0.267 0.182 0.832
CpG9 H 0.052 0.721 0.557 0.428 0.598 0.488 0.330 0.358
T 0.815 0.754 0.868 0.922 0.643 0.188 0.326 0.522
CpG10 H <0.001 0.218 0.114 0.808 0.625 0.447 0.964 0.521
T 0.275 0.775 0.868 0.976 0.623 0.590 0.458 0.128
CpG11 H 0.016 0.776 0.990 0.536 – – – –
T 0.615 0.588 0.456 0.248 – – – –
Average H 0.450 0.203 0.553 0.453 0.076 0.727 0.847 0.850
T 0.386 0.656 0.584 0.146 0.424 0.241 0.389 0.919
Data are presented as P values. Statistically significant P values <0.05 are in italic. H stands for non-tumor tissues and T for tumor tissues.
Table 3 Impact of clinical variables on overall survival of patients 
with lung cancer
Variable P value
Age at diagnosis 0.172
Histologic type 0.558
T-stage 0.354
N-stage 0.0007
TNM-stage 0.023
FEV1 0.587
Statistically significant P values for log-rank test <0.05 are in italic.
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CpG2 (ρ=0.49, P=0.002) and average methylation (ρ=0.34, 
P=0.044). On the contrary, weak negative correlation was 
observed between ASC/TMS1/PYCARD methylation level 
of CpG9 in non-tumor tissue and FEV1 (ρ=−0.40, P=0.032). 
All the results are presented in the Table 5. 
Discussion
Our study aimed to quantify the methylation status of ASC/
TMS1/PYCARD and MyD88 genes by pyrosequencing 
approach and to evaluate if this could be utilized as potential 
biomarkers in diagnosis and prognosis of lung cancer. To 
the best of our knowledge, there is no published data on 
quantification of the overall methylation status of the 
selected CpG sites, as well as the methylation at specific loci 
by pyrosequencing approach. The analysis was performed 
for ASC/TMS1/PYCARD and MyD88 promoter regions in 
the tumor and adjacent non-malignant tissues of the 
NSCLC patient. Here we report decreased methylation of 
the ASC/TMS1/PYCARD and MyD88 in NSCLC. We 
found that the overall methylation level of tested genes in 
NSCLC samples is low, in both tumor and adjacent non-
tumor tissue. However, we observed a significantly 
decreased methylation of the tumor tissues compared to 
non-malignant tissues that result in increased mRNA and 
protein expression. All of the above mentioned studies, in 
the Introduction part of this study, reported aberrant 
hypermethylation of the ASC/TMS1/PYCARD promoter. 
However methylation status in those studies was analysed 
by semi-quantitative approach, predominantly by MSP. In 
our study we went beyond previously published data and, 
for the first time, quantified the methylation status of ASC/
TMS1/PYCARD and MyD88 promoter regions in NSCLC 
by a bisulphite pyrosequencing approach. To the best of our 
knowledge, there is only one study published so far by 
Wong et al., where the methylation status of ASC/TMS1/
PYCARD was quantified by pyrosequencing (43). They 
quantified methylation status of six tumor suppressor genes, 
including ASC/TMS1/PYCARD, in exfoliated epithelial 
cells isolated from breast milk of healthy women. They 
found that the overall methylation status of 12 tested CpG 
sites in the ASC/TMS1/PYCARD promoter is 3.67%, which 
is low and is consistent with our results. In the case of 
MyD88 we are the first to report both overall methylation 
and methylation at specific CpG sites, as previously 
mentioned. As already discussed, published data on ASC/
TMS1/PYCARD promoter methylation status does is not 
consistent with our results. Aiming to resolve the apparent 
discrepancy, first we have examined publicly available whole 
genome methylation data (450k Infinium chip) obtained 
through The Cancer Genome Atlas project (TCGA) (44). 
The data was visualized through the recently developed 
USCS XENA (ht tps : / /www.biorx iv.org/content/
early/2018/08/28/326470) viewer (45). Out of 13 CpG sites 
included in the whole genome 450k Infinium methylation 
array, only 2 fell within the immediate vicinity of ASC/
TMS1/PYCARD  start site and overlapped with the 
pyrosequenced regions (Figure S1). However, the TCGA 
Table 4 Impact of ASC/TMS1/PYCARD and MYD88 methylation 
levels on overall survival of patients with lung cancer
Methylation/ 
CpG site
Tissue type
ASC/TMS1/ 
PYCARD
MYD88
CpG1 H 0.278 0.927
T 0.485 0.114
CpG2 H 0.399 0.510
T 0.120 0.927
 CpG3 H 0.915 0.560
T 0.136 0.333
CpG4 H 0.019 0.925
T 0.019 0.925
CpG5 H 0.385 0.497
T 0.107 0.974
CpG6 H 0.438 0.484
T 0.334 0.994
CpG7 H 0.017 0.991
T 0.427 0.409
CpG8 H 0.414 0.962
T 0.991 0.896
CpG9 H 0.858 0.398
T 0.427 0.405
CpG10 H 0.163 0.927
T 0.324 0.945
CpG11 H 0.935 –
T 0.989 –
Average H 0.120 0.940
T 0.427 0.135
Statistically significant P values for log-rank test <0.05 are in 
italic. H stands for non-tumor tissues and T for tumor tissues.
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data was only available for CpG6 (corresponding to 
cg09866102;  I l lumina 450K ID) while  for  CpG7 
(corresponding to cg09587549; Illumina 450K ID) no data 
was available as this probe was probably filtered out during 
the initial analysis of the TCGA data by the consortium. 
The data from lung adenocarcinoma subset (LUAD; 
Figure S2) indicated that cancer tissue was slightly 
hypomethylated at the cg09866102 probe position (mean 
beta value 0.0386; n=457) compared to patient matched 
normal/non-tumor tissue (mean beta value 0.0432; n=32). 
Although small, the difference was significant (P=2.441e-8). 
On the other hand the situation in both the TCGA lung 
squamous cell carcinoma (LUSC) primary carcinoma subset 
and the combined TCGA lung cancer (LUNG) primary 
carcinoma dataset (Figure S3) was opposite. In the case of 
squamous cell cancer subset, normal tissue had a mean of 
0.0191 (n=43) and cancer a mean of 0.0239 (n=372) beta 
methylation value while in the combined set mean normal 
tissue methylation was 0.0236 (n=75) and cancer 0.0284 
(n=830). Taken together, TCGA data indicate that different 
lung cancer subgroups do show some differences in 
methylation patterns with adenocarcinoma exhibiting 
decreased methylation near the ASC/TMS1/PYCARD gene 
transcription start site, while squamous carcinoma show 
slightly increased methylation upstream of the start site. 
Interestingly, this finding is supported by our study; when 
we stratified the samples in different histopathological 
subgroups (adenocarcinoma and squamous cell cancer) we 
observed above mentioned pattern—adenocarcinoma 
tumors were slightly, but statistically significantly 
hypomethylated (data not shown). The TCGA data also 
indicated that methylation varied considerably depending 
on the position relative to the start site (from almost zero in 
the immediate vicinity of the start to 60–70% on either side 
of the gene). On the other hand, it has also been shown that 
DNA hypomethylation is the important and most constant 
companion to hypermethylation of the genome in many 
cancers (46), including lung cancer (47). It seems that DNA 
hypomethylation is the initial epigenetic abnormality in 
human tumors (48). DNA hypomethylation in repetitive 
sequences has been reported to occur in early stages of 
squamous cel l  lung cancer,  and indiv iduals  with 
Figure 5 Clinicopathologic characteristics and methylation of ASC/TMS1/PYCARD CpG sites with significant impact on overall survival in 
patients with lung cancer: (A) N-stage; (B) TNM-stage; (C) ASC/TMS1/PYCARD CpG4 in non-malignant tissue; (D) ASC/TMS1 CpG4 in 
tumor tissue; (E) ASC/TMS1/PYCARD CpG7 in non-malignant tissue. Tick marks indicate censored cases.
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hypomethylation in repetitive elements are at a high risk of 
developing and dying from cancer (49). Indeed, a result of 
our association study shown that hypomethylation of CpG4 
and CpG8 sites in the ASC/TMS1/PYCARD promoter is 
associated with shorter overall survival. Also, it is very 
important to emphasize that common use of semi-
quantitative approach for methylation analysis, like MSP, is 
prone to produce false positive results (50). As it was shown 
by Claus et al., when direct comparison of MSP and 
pyrosequencing data was conducted on two genes 
epigenetically silenced in acute myeloid leukemia (AML), 
ID4 and SFRP, they determine significant overestimation of 
DNA methylation data by MSP. Therefore, they suggested 
quantitative approaches, like pyrosequencing, for precise 
characterization and reliable biomarker detection of 
aberrant DNA methylation in patient samples (51). With 
the aim of further confirmation of our results, we analysed 
mRNA and protein expression and found that decreased 
methylation status, in our cohort study, correlate with 
increased protein expression, while increased mRNA 
expression was confirmed only for ASC/TMS1/PYCARD. 
These results are mainly consistent with the results of the 
methylation status, however, one should keep in mind that 
difference in methylation status, between tumor and non-
malignant tissues, although statistically significant, are very 
small. Therefore, further functional studies that are out of 
scope of presented study are required to explore if such a 
small differences could impact mRNA/protein expression. 
Beside the quantification of the methylation status, we also 
analysed the correlation of methylation status of each tested 
CpG site with overall survival and tumor growth of NSCLC 
patients. We found that hypomethylated CpG4 and CpG8 
sites in ASC/TMS1/PYCARD promoter are associated with 
reduced OS of NSCLC patients. We further speculate that 
hypomethylation of ASC/TMS1/PYCARD promoter region 
may correlate with tumor growth. Statistical analysis 
showed that higher methylation of CpG8 in the ASC/
TMS1/PYCARD promoter is associated with TNM grade 2. 
As for overall survival, this was independent of tumor type. 
Potential translational usage of this finding could be the 
detection of transformation of tumor tissue from early stage 
to more severe forms of tumors. For Myd88 we did not find 
any correlation of methylation status with overall survival 
and tumor growth for any of the tested CpG sites. In the 
end, although we demonstrate here that differentially 
methylated CpG sites are promising prognostic and 
diagnostic biomarker candidates, the present work was 
carried out on a relatively small group of participants and 
was focused only on two genes. The results we present here 
require further replication in a larger cohort. Our study is 
mainly a demonstration of the concept that highlights the 
utility of the methylation status of certain genes that can be 
translated into the clinical practice as reliable diagnostic 
markers, when differentiation of tumor and non-tumor 
tissues is difficult, and as potential predictors for different 
clinical outcome in the NSCLC patients. 
Table 5 Correlation between pulmonary function expressed by 
forced expiratory volume in one second (FEV1) and ASC/TMS1/
PYCARD and MYD88 methylation levels
CpG site Tissue type
ASC/TMS1/PYCARD MYD88
ρ* P value ρ* P value
CpG1 H 0.03 0.872 −0.28 0.094
T 0.13 0.507 0.36 0.030
CpG2 H −0.20 0.302 −0.21 0.219
T 0.22 0.246 0.49 0.002
CpG3 H −0.29 0.131 0.09 0.590
T 0.12 0.551 0.10 0.571
CpG4 H −0.21 0.265 −0.17 0.316
T 0.00 0.988 0.10 0.557
CpG5 H 0.17 0.379 −0.02 0.933
T 0.24 0.212 0.27 0.113
CpG6 H −0.17 0.367 −0.14 0.417
T −0.01 0.962 −0.05 0.756
CpG7 H 0.00 0.988 −0.09 0.608
T 0.16 0.395 −0.08 0.648
CpG8 H −0.32 0.090 −0.11 0.514
T 0.12 0.538 −0.08 0.650
CpG9 H −0.40 0.032 0.05 0.776
T 0.07 0.720 −0.14 0.402
 CpG10 H 0.35 0.064 0.07 0.673
T 0.08 0.679 −0.08 0.646
CpG11 H 0.06 0.767 – –
T −0.15 0.432 – –
Average H −0.11 0.571 −0.23 0.176
T 0.00 0.988 0.34 0.044
*, statistically significant Spearman’s rank correlation coefficients 
(ρ) with P values <0.05 are in italic. H stands for non-tumor 
tissues and T for tumor tissues.
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Conclusions 
We demonstrated that differentially methylated CpG 
sites in the promotor region of ASC/TMS1/PYCARD 
and MyD88 genes could serve for accurate differentiation 
between malignant and nonmalignant lung tissue specimens. 
Methylation status of the CpG11 site in the ASC/TMS1/
PYCARD promoter as well as CpG1 and 2 in the MyD88 
promoter could be considered as good and reliable 
biomarkers for distinguishing non-tumor from tumor 
tissue. We also demonstrated that ASC/TMS1/PYCARD 
CpG4 and CpG8 hypomethylation is associated with 
decreased overall survival, indicating the prognostic value 
of tested CpG sites. The published data on this subject is 
very limited, and for the confirmation of our results a larger 
number of samples, consisted of different lung tumor types 
and stages/grades should be analysed. 
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Table S1 Methylation status (%) of ASC/TMS1/PYCARD promoter in tumour and adjacent non-tumour tissues of the NSCLC patients
Sample ID
CpG1 (+52)† CpG2 (+49) CpG3 (+33) CpG4 (−134) CpG5 (−129) CpG6 (−124) CpG7 (−116) CpG8 (−92) CpG9 (−76) CpG10 (−71) CpG11 (−65)
H T H T H T H T H T H T H T H T H T H T H T
1-080 3.73 6.51 8.29 11.32 2.57 5.17 4.63 6.77 9.67 9.89 10.59 17.51 7.275 10.39 6.435 10.39 4.435 3.675 7.24 5.25 10.51 5.7
1-083 5.59 3.97 9.27 8.67 2.38 3.25 5.28 4.87 9.43 5.89 11.33 12.70 9.345 7.47 7.445 6.745 3.685 5.085 4.5 5.795 5.57 5.13
1-085 4.70 4.89 9.33 11.58 2.39 4.23 5.02 6.85 8.30 9.47 12.80 11.10 7.85 8.92 7.63 5.885 5.5 8.895 6.36 7.075 5.92 7.33
1-091 3.63 0.00 7.21 8.66 2.57 8.25 6.26 0.00 8.78 7.56 9.61 13.03 8.735 0 7.675 0 4.505 3.88 10.9 5.48 12.66 5.35
1-092 4.89 19.08 9.18 21.01 2.37 15.96 4.18 11.12 7.62 21.32 11.82 25.19 8.71 11.73 8.085 11.16 15.26 4.07 8.035 5.325 16.83 2.975
1-097 4.61 3.88 10.17 8.41 3.47 2.89 6.52 5.40 10.53 7.09 15.41 11.80 10.75 6.605 8.655 7.195 6.515 4.435 5.995 5.71 11.79 5.69
1-101 6.09 2.51 10.70 6.17 3.39 2.10 4.39 3.57 8.31 4.74 11.45 9.53 7.9 6.145 6.74 5.81 8.88 4.17 5.16 5.145 10.75 5.13
1-103 5.30 3.68 11.17 9.74 2.25 6.84 6.17 6.71 8.64 6.68 14.90 13.75 10.03 6.54 8.33 5.705 5.13 4.415 3.775 5.58 9.16 4.98
1-104 5.50 2.83 12.49 5.98 3.35 1.77 6.79 4.13 10.90 4.53 17.10 11.21 9.855 6.945 10.37 5.98 4.85 5.765 5.7 6.465 9.125 5.875
1-108 4.10 3.64 8.36 7.97 3.93 3.27 5.74 4.62 7.48 6.69 13.54 11.23 8.595 9.62 7.83 5.63 5.65 6.46 6.135 7.56 7.705 7.61
1-113 3.17 4.09 6.73 8.22 3.19 0.00 5.66 3.57 8.59 7.78 13.80 15.03 8.445 8.605 6.35 8.62 4.675 4.995 6.32 5.33 8.5 2.745
1-116 3.67 4.41 7.51 12.54 3.24 4.34 5.79 5.51 8.65 8.04 13.79 9.70 8.72 9.895 8.65 11.05 4.59 3.92 5.695 4.73 8.32 6.915
1-120 3.61 7.83 8.56 10.79 3.27 10.88 6.28 6.37 10.96 11.46 12.58 16.91 8.335 8.355 5.335 7.94 3.795 4.815 6.09 5.215 6.89 4.475
1-124 3.33 3.20 7.85 5.75 3.56 3.01 3.25 3.99 10.42 5.09 12.45 10.23 8.48 6.815 6.025 4.725 3.645 3.72 5.175 4.255 7.36 4.69
1-126 4.74 2.69 8.85 4.69 3.28 2.60 5.50 4.20 9.61 3.66 13.90 7.13 8.795 4.14 5.705 3.17 3.705 4.925 6.45 5.89 7.485 5.65
1-127 4.58 3.30 7.44 6.71 4.43 2.25 7.91 5.30 7.84 5.48 12.35 9.32 6.585 6.135 6.86 4.67 5.835 6.83 5.47 6.005 8.59 6.93
1-135 5.99 4.16 8.99 9.41 4.18 4.74 5.70 5.25 7.81 7.22 12.72 11.30 9.47 8.865 9.315 6.425 5.865 3.185 3.66 4.265 5.335 6.97
1-143 3.90 2.90 8.65 8.46 3.01 2.37 4.76 4.05 8.32 7.13 13.11 10.98 8.045 6.395 7.525 6.4 4.155 3.065 4.805 1.455 7.51 5.58
1-144 4.99 3.78 11.18 7.03 2.94 2.40 6.79 4.04 12.26 6.08 16.70 10.66 9.585 5.095 8.815 5.63 3.305 2.58 7.265 2.63 8.855 5.275
1-152 5.20 3.42 9.23 8.50 4.31 2.50 4.72 5.93 8.17 7.69 11.57 10.16 9.48 8.015 6.785 5.045 3.88 2.935 5.07 4.055 4.13 2.795
1-155 7.67 4.40 9.92 8.63 5.47 3.46 9.40 4.54 13.35 10.06 11.96 12.37 11.45 8.4 13.12 6.41 5.125 2.655 5.995 3.065 6.575 4.865
1-163 3.46 6.49 7.70 9.04 5.21 6.70 5.96 5.75 8.43 7.32 14.74 14.64 6.015 8.39 8.215 10.18 4.565 3.73 3.93 4.645 5.265 5.355
1-166 7.26 4.25 9.79 10.38 5.57 4.18 6.23 5.14 8.41 7.47 14.70 11.64 11.26 8.905 7.455 7.995 4.05 1.605 3.83 1.825 5.165 0
1-170 4.85 4.09 9.66 8.68 3.97 3.26 6.35 6.91 8.47 7.04 14.44 13.79 9.07 7.455 7.945 5.09 4.435 3.25 4.32 3.275 4.045 4.03
1-171 5.06 3.58 9.73 7.92 4.08 3.72 5.46 3.76 9.08 7.59 13.77 13.00 8.3 6.075 7.18 7.9 3.78 2.435 3.735 2.35 5.805 1.655
1-178 3.70 4.53 10.44 9.54 3.20 2.26 6.07 6.43 9.57 8.30 14.75 10.50 9.55 8.25 9.285 5.805 3.88 1.745 5.155 4.16 6.705 4.91
1-184 4.06 5.75 9.86 11.28 4.47 3.63 7.23 6.53 9.57 11.17 13.49 17.20 9.35 10.85 8.835 8.215 4.825 3.51 5.76 5.515 8.395 7.05
1-195 4.92 10.05 9.06 14.19 3.74 10.82 6.44 12.50 10.06 13.07 14.06 18.19 8.985 12.82 6.35 11.32 4.78 7.61 5.5 7.535 7.805 9.415
1-197 4.89 4.02 9.26 8.63 4.88 2.77 5.06 6.39 8.03 6.09 12.82 12.02 8.43 6.965 5.575 6.71 4.08 1.885 5.415 2.23 7.365 1.15
1-209 4.07 3.33 12.11 7.85 5.25 2.77 5.20 6.01 8.79 7.42 12.93 11.70 7.47 8.295 6.84 6.64 3.73 2.46 4.225 2.89 5.77 3.38
1-213 5.41 4.52 12.58 10.07 3.58 5.08 6.28 6.87 9.33 9.40 18.60 13.55 10.85 8.17 10.3 7.21 3.325 1.01 3.53 3.965 5.87 1.63
1-215 4.59 4.53 9.38 9.02 4.86 2.83 7.52 5.80 10.91 6.35 15.46 13.43 8.745 7.32 8.645 7.575 3.2 2.99 4.995 1.84 5.605 0
1-225 4.26 3.46 9.80 6.38 3.59 3.55 6.16 4.40 9.29 5.39 12.10 9.68 9.14 5.535 7.3 5.525 4.695 2.915 6.52 3.6 6.455 3.69
1-228 5.79 9.14 10.35 11.71 2.79 10.22 6.43 10.37 8.32 10.86 14.38 16.29 9.11 12.72 7.68 10.61 5.305 6.86 6.415 4.835 9.195 0
1-233 4.59 2.69 10.64 6.55 4.28 3.53 7.58 4.59 7.85 6.99 14.70 10.27 12.34 5.51 6 4.32 3.89 6.91 4.895 6.485 6.08 0
1-238 4.16 4.26 9.98 5.56 4.47 1.87 6.55 3.45 9.29 5.66 14.15 10.80 8.84 5.78 7.585 5.35 4.175 6.91 7.335 9.025 6.44 9.415
†, represents distance from transcriptional start site. Each number represents an average value of the methylation (%) of at least 3 individual PCR/Pyrosequencing reactions, from the same bisulphite-
converted DNA. SDs for triplicates should be less than 1%.
Supplementary
Table S2 Methylation status (%) of MyD88 promoter in tumour and adjacent non-tumour tissues of the NSCLC patients
Sample ID
CpG1 (−253)† CpG2 (−256) CpG3 (−267) CpG4 (−278) CpG5 (−210) CpG6 (−216) CpG7 (−222) CpG8 (−146) CpG9 (−151) CpG10 (−167)
H T H T H T H T H T H T H T H T H T H T
1-001 16.09 11.47 23.97 14.95 13.57 10.61 21.55 17.4 6.2 3.68 5.805 7.435 5.77 9.83 5.425 3.725 1.975 2.33 4.88 2.415
1-003 13.08 11.41 19.9 18.85 11.48 6.33 16.8 12.78 11.13 8.69 5.655 11.88 3.07 3.735 6.72 6.535 2.325 0 0 0
1-004 12.6 6.055 19.17 13.29 6.59 9.095 11.22 12.19 10.29 6.235 11.8 0 3.44 11.42 9.865 0 2.84 0 0 0
1-005 12.57 8.51 19.2 14.58 9.715 6.225 16.79 14.43 6.36 4.55 7.205 10.23 9.21 13.4 5.47 0 8.585 0 4.83 0
1-006 12.96 7.09 19.07 10.23 5.17 4.955 13.62 7.98 3.45 0 5.535 10.37 6.41 11.25 11.34 2.845 9.725 0 3.61 6.54
1-008 3.495 12.07 13.36 18.94 6.525 0 16.15 12.2 4.295 7.27 11.16 0 0 0 10.11 3.865 6.055 0 3.84 3.055
1-009 13.04 12.76 18.27 17.37 13.6 8.945 19.06 14.51 7.125 9.39 14.33 3.165 0 0 7.7 0 6.885 0 6.975 3.625
1-010 12.55 8.68 20.42 16.27 4.965 3.47 16.15 12.49 7.615 0 15.64 16.04 0 19.59 7.895 9.82 0 2.96 3.65 6.09
1-012 9.315 7.09 12.79 15.9 3.54 6.45 9.775 9.36 10.01 9.415 6.465 0 9.31 0 3.39 9.865 4.4 3.22 3.8 6.455
1-014 9.08 7.625 14.16 13.93 7.435 0 12.46 0.005 8.14 3.575 3.945 11.17 2.51 9.65 7.765 7.67 0 0 0 8.055
1-015 12.37 11.4 14.05 14.24 7.78 3.3 8.85 8.575 1.74 12.19 6.655 14.56 0 0 4.7 6.955 6.52 4.295 9.18 6.635
1-016 13.15 7.63 20.79 9.52 4.79 8.68 16.17 12.18 0.745 0 6.155 5.545 0 2.2 5.185 9.03 0 2.745 3.345 0
1-080 10.42 14.15 18.2 21.08 7.4 7.765 19.05 11.49 8.91 0 5.235 5.34 8.695 4.63 5.76 4.92 0 0 0 0
1-082 11.89 3.9 18.19 8.495 4.275 6.09 13.29 15.47 5.13 0 6.94 0 4 0 0 0 0 0 5.25 0
1-083 8.845 13.22 17.95 23.99 4.035 33.01 10.9 24.5 5.14 2.655 3.425 2.455 4.225 2.42 3.665 17.04 0 0 5.9 0
1-091 5.86 10.3 29.58 16.64 18.76 5.595 14.3 12.67 3.13 2.935 13.02 4.47 5.46 4.7 4.57 2.26 4.2 0 5.81 4.93
1-092 14.42 8.79 11.91 17.44 10.16 3.2 45.77 26.82 13.01 0 16.97 8.195 15.21 7 14.57 0 0 0 12.58 2.695
1-097 14.88 4.13 26.24 6.435 10.82 5.655 20.79 10.46 6.81 2.465 6.07 1.895 4.895 7.365 6.725 1.84 3.275 0 10.17 0
1-101 14.33 6.46 23.23 11.94 7.155 4.428 27.15 18.64 8.36 1.233 7.595 5.045 0 7.183 4.7 0.92 7.16 0 5.33 1.348
1-104 17.13 9.205 24.87 9.965 5.185 5.43 12.33 16.36 5.82 4.24 4.98 8.005 4.645 6.45 2.635 8.505 0 0 7.385 2.485
1-108 13.92 8.05 17.28 15.98 3.335 6.525 11.3 5.41 1.92 3.455 2.885 5.99 4.04 4.99 4.72 6.485 0 1.57 6.085 2.03
1-113 10.59 4.67 18.45 17.9 7.935 6.275 17.52 12.56 3.185 2.73 0 6.955 1.54 0 1.97 0 0 0 1.975 5.1
1-116 8.685 7.19 17.62 11.51 5.25 0 13.3 8.895 0 3.46 0 6.31 0 5.07 2.195 0 0 0 5.08 0
1-120 11.21 11.02 16.41 4.86 5.375 0 15.48 2.685 2.26 5.615 1.62 3.605 1.55 6.98 4.915 0 1.685 0 4.48 3.695
1-126 16.76 10.47 21.04 9.965 6.485 6.98 14.98 9.505 1.805 2.87 0 5.535 0 0 4.275 3.58 0 0 4.535 2.715
1-127 11.68 8.42 13.66 11.49 7.745 4.375 9.715 20.08 0 4.01 0 0 0 2.585 4.245 11.2 0 0 5.395 0
1-135 22.35 3.215 30.23 10.18 13.13 6.96 27.05 14.48 6.745 3.255 3.83 6.86 6.8 2.82 5.155 9.395 0 3 5.28 0
1-143 15.03 5.76 17.89 7.36 8.36 7.54 12.53 9.765 1.62 2.625 2.46 2.675 2.375 2.945 5.4 6.485 0 0 6.205 0
1-144 9.42 7.135 14.14 7.13 8.35 2.05 20.83 8.78 5.515 2.005 5.73 5.67 0 4.32 1.81 3.715 0 0 7.745 0
1-152 13.24 2.895 17.07 7.845 8.46 12.21 8.98 6.94 6.515 6.81 6.435 6.275 0 4.225 2.11 18.02 0 0 5.955 0
1-155 11.97 7.605 16.02 14.73 5.91 2.52 9.14 12.93 2.5 4.32 0 1.07 3.615 3.035 6.845 7.205 0 2.41 2.85 4.5
1-163 15.45 13.6 18.39 9.695 7.23 2.805 10.86 9.985 1.86 1.31 2.68 5.375 0 3.44 4.73 5.59 0 1.59 2.945 4.955
1-166 13.61 2.745 21.74 5.025 6.71 3.735 15.53 8.71 2.565 1.55 2.14 1.405 3.985 1.885 4.495 5.4 0 0 2.805 6.16
1-170 15.02 8.335 16.02 14.9 9.635 6.02 12.76 10.46 2.765 4.445 0 1.045 2.43 3.775 0 7.46 0 0 8.33 1.875
1-171 8.62 10.32 17.72 6.765 0 2.02 8.81 9.9 4.955 0 0 8.235 2.92 6.12 9.02 0 4.9 0 0 6.4
1-184 12.23 7.855 17.78 13.75 5.36 7.245 14.26 12.72 8.82 2.645 6.3 6.67 1.61 2.565 5.45 8.625 0 2.445 6.71 0
1-193 14.61 11.73 16.75 13.35 4.23 8.37 9.635 14.76 0 2.465 5.525 2.51 0 2.255 0 3.53 0 0 6.995 5.175
1-195 15.69 8.055 19.28 13.52 11.78 6.555 26.52 10.17 0 4.475 0 2.905 0 0 7.06 7.3 5.01 0 4.11 6.75
1-197 14.05 24.24 23.09 33.77 7.995 14.11 13.55 28.45 2.975 1.755 0 0 7.465 6.57 0 10.96 0 0 2.955 18.62
1-207 16.1 2.92 21.99 8.3 7.615 4.205 14.45 4.97 0 5.74 0 6.82 2.535 2.455 2.855 0 0 0 3.57 0
1-209 12.63 6.14 20.14 11.66 5.32 2.285 12.45 11.02 3.19 1.2 1.13 5.27 3.755 5.675 4.775 7.4 4.245 0 4.63 7.535
1-213 10 6.905 15.78 9.6 5.13 6.615 15.35 12.13 1.81 1.95 2.175 1.495 1.725 1.885 4.96 2.81 0 4.975 8.115 0
1-225 11.41 7.44 16 12.75 4.655 9.69 9.405 11.57 1.94 1.705 1.805 0 2.18 5.545 3.48 3.395 3.355 0 4.765 7.4
†, represents distance from transcriptional start site. Each number represents an average value of the methylation (%) of at least 3 individual PCR/Pyrosequencing reactions, from the same bisulphite-converted DNA. 
SDs for triplicates should be less than 1%.
Table S3 Expression of 84 genes involved in inflammasome signaling (RT2 Profiler PCR Array-PAHS-097ZA-2) on mRNA level
Gene symbol Gene name Level of regulation (fold-change)
Up-regulated genes
CARD18 Caspase recruitment domain family member 18 143.07
AIM2 Absent in melanoma 2 10.44
PANX1 Pannexin 1 8.4
FADD Fas associated via death domain 8.02
MOK MOK protein kinase 7.37
IRAK1 Interleukin 1 receptor associated kinase 1 6.93
TNFSF4 Tumor necrosis factor superfamily member 4 5.96
NFKBIB NFKB inhibitor beta 5.9
MAPK13 Mitogen-activated protein kinase 13 5.44
NOD2 Nucleotide binding oligomerization domain containing 2 5.14
HSP90AB1 Heat shock protein 90 alpha family class B member 1 4.88
NLRX1 NLR family member X1 4.83
HSP90B1 Heat shock protein 90 beta family member 1 4.37
MAPK12 Mitogen-activated protein kinase 12 4.37
RELA RELA proto-oncogene. NF-kB subunit 3.76
BCL2L1 BCL2 like 1 3.74
XIAP X-linked inhibitor of apoptosis 3.51
MAP3K7 Mitogen-activated protein kinase 7 3.36
PEA15 Phosphoprotein enriched in astrocytes 15 3.13
HSP90AA1 Heat shock protein 90 alpha family class A member 1 3.05
MAPK9 Mitogen-activated protein kinase 9 3.03
MAPK1 Mitogen-activated protein kinase 1 2.95
TRAF6 TNF receptor associated factor 6 2.9
TAB2 TGF-beta activated kinase 1/MAP3K7 binding protein 2 2.86
CXCL1 C-X-C motif chemokine ligand 1 2.83
SUGT1 SGT1 homolog. MIS12 kinetochore complex assembly cochaperone 2.72
TAB1 TGF-beta activated kinase 1/MAP3K7 binding protein 1 2.65
IL18 Interleukin 18 2.59
IKBKG Inhibitor of kappa light polypeptide gene enhancer in B-cells. kinase gamma 2.46
RIPK2 Receptor interacting serine/threonine kinase 2 2.33
CCL2 C-C motif chemokine ligand 2 2.3
PYCARD PYD and CARD domain containing 2.27
CHUK Conserved helix-loop-helix ubiquitous kinase 2.16
IL1B Interleukin 1 beta 2.05
MAPK8 Mitogen-activated protein kinase 8 2.02
CTSB Cathepsin B 2.02
Down-regulated genes
IL33 Interleukin 33 −11.52
IL6 Interleukin 6 −8.29
NLRP9 NLR family pyrin domain containing 9 −5.98
CD40LG CD40 ligand −3.93
IL12A Interleukin 12A −3.53
PTGS2 Prostaglandin-endoperoxide synthase 2 −2.64
TXNIP Thioredoxin interacting protein −2.36
CXCL2 C-X-C motif chemokine ligand 2 −2.29
MEFV Mediterranean fever −2
Genes with no change in expression
BIRC2 Baculoviral IAP repeat containing 2 1.95
MAPK3 Mitogen-activated protein kinase 3 1.89
IRF2 Interferon regulatory factor 2 1.8
NFKB1 Nuclear factor kappa B subunit 1 1.75
CASP5 Caspase 5 1.65
CASP1 Caspase 1 1.62
IL12B Interleukin 12B 1.51
NFKBIA NFKB inhibitor alpha 1.5
IFNG Interferon gamma 1.49
IFNB1 Interferon beta 1 1.46
TIRAP TIR domain containing adaptor protein 1.39
IKBKB Inhibitor of kappa light polypeptide gene enhancer in B-cells. kinase beta 1.39
CARD6 Caspase recruitment domain family member 6 1.27
NLRP6 NLR family pyrin domain containing 6 1.21
IRF1 Interferon regulatory factor 1 1.2
MYD88 Myeloid differentiation primary response 88 1.17
NLRP1 NLR family pyrin domain containing 1 1.08 
NOD1 Nucleotide binding oligomerization domain containing 1 −1.04
NLRC5 NLR family CARD domain containing 5 −1.06
P2RX7 Purinergic receptor P2X 7 −1.25
CASP8 Caspase 8 −1.31
NLRP12 NLR family pyrin domain containing 12 −1.39
NLRP3 NLR family pyrin domain containing 3 −1.41
CCL5 C-C motif chemokine ligand 5 −1.41
MAPK11 Mitogen-activated protein kinase 11 −1.45
TNF Tumor necrosis factor −1.49
CFLAR CASP8 and FADD like apoptosis regulator −1.53
NLRC4 NLR family CARD domain containing 4 −1.64
CIITA Class II major histocompatibility complex transactivator −1.71
PSTPIP1 Proline-serine-threonine phosphatase interacting protein 1 −1.73
NAIP NLR family apoptosis inhibitory protein −1.76
BIRC3 Baculoviral IAP repeat containing 3 −1.79
Shown are the fold change values in arbitrary units. Data were normalized to B2M housekeeping gene.
Figure S1 Genomic position of the ASC/TMS1/PYCARD gene with locations of pyrosequencing regions and Infinium 450K whole 
methylation array CPG probes visualized in USCS Genome browser. CPG island is indicated in green while thin blue vertical line indicates 
CpG position assayed by both methods. Note that ASC/TMS1/PYCARD is transcribed in the opposite direction indicated by small arrows 
within the gene region.
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cohort: TCGA Lung Adenocarcinoma (LUAD) (n=489)
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Figure S2 Beta values of the TCGA Lung Adenocarcinoma samples in the vicinity of ASC/TMS1/PYCARD gene visualized in XENA USCS 
browser. Note that for the CpG probe cg09866102 assayed by both methods data indicates small reduction of mean methylation value in 
cancer compared to matched control tissue of the same patient. Non primary tumors and samples with no measurements were excluded. 
TCGA stands for The Cancer Genome Atlas project.
Figure S3 Beta values of the TCGA Lung Squamous Cell Carcinoma samples (top) and combined TCGA Lung Cancer dataset (bottom) 
visualized in XENA USCS browser. In both cases non primary tumors and samples with no measurements were excluded. TCGA stands for 
The Cancer Genome Atlas project.
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cohort: TCGA Lung Squamous Cell Carcinoma (LUSC) (n=626)
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